Prevalence of Hepatitis C virus infection in HIV infected Patients - Oyewole, Tunji
39,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
20 °P sammeln
  • Broschiertes Buch

The menace of Humman Immunodeficiency virus acting alone is enormous. More complicated is a combination of both Humman Immunodeficiency virus and Hepatitis C virus occurring together in an individual. These two viruses unfortunately share common routes for transmission and therefore coinfection of both viruses has been found to be prevalent among HIV infected individuals. Coinfection worsens and quickens the evolution of HCV related liver disease in the coinfected, leading to morbidity and mortality in them. Insight into potent modes of transmission of these two viruses then helps to gain…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
The menace of Humman Immunodeficiency virus acting alone is enormous. More complicated is a combination of both Humman Immunodeficiency virus and Hepatitis C virus occurring together in an individual. These two viruses unfortunately share common routes for transmission and therefore coinfection of both viruses has been found to be prevalent among HIV infected individuals. Coinfection worsens and quickens the evolution of HCV related liver disease in the coinfected, leading to morbidity and mortality in them. Insight into potent modes of transmission of these two viruses then helps to gain better control in disease prevention and management of the coinfected. This therefore has necessitated this work in an African setting where most infections are thought to be endemic. Dr Tunji Oyewole MB;BS,FWACP.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr Tunji Olugbenga Oyewole is a Physician with Fellowship of the West African College of Physicians.He currently practices as a middle grade physician in the UK.He is just about to conclude a Masters degree in Pharmaceutical Medicine with Clinical Pharmacology at the Kings College London to be able to oversee Clinical trials for new medicines.